Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending March 01, 2005. The report details a share repurchase transaction executed on February 28, 2005, and updates regarding directors' interests in company shares.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity figures. It focuses exclusively on capital structure changes related to share buybacks and treasury holdings.
- Shares Repurchased: 750,000 Ordinary shares.
- Repurchase Price: 1,249.98 pence per share.
- Total Treasury Shares: 76,248,000 shares (post-transaction).
- Shares in Issue: 5,863,461,892 shares (excluding Treasury shares).
Material Changes
The primary material change is the reduction of outstanding shares through a buyback authorized by shareholders at the Annual General Meeting on May 17, 2004. Additionally, the GlaxoSmithKline Employee Trust transferred 24,246 Ordinary Shares to participants in the SmithKline Beecham Employee Share Option Plan 1991 on February 28, 2005.
Outlook and Management Commentary
Management intends to hold the repurchased shares in Treasury. The filing explicitly states that this announcement does not constitute an offer or solicitation to purchase securities in any jurisdiction. No forward-looking guidance, risk factors, or unusual items are disclosed in this specific report.
Investor Verification Checklist
- Verify the total cost of the 750,000 share repurchase against the stated price of 1,249.98 pence.
- Confirm the updated total share count (5,863,461,892 in issue) against subsequent filings.
- Review the remaining authorization for share buybacks under the May 17, 2004 shareholder mandate.
- Check for any impact of the 24,246 shares transferred from the GSK Trust on executive compensation reporting.